We are pleased to announce that the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) raw dataset is now available for data access request via the AD Workbench.
Information about the raw AMYPAD PNHS dataset
The AMYPAD Prognostic and Natural History Study (PNHS) is an open-label, prospective, multicentre, cohort study linked to a variety of European Parent Cohorts.
AMYPAD PNHS aims to improve disease modelling efforts and individualised risk stratification within the context of Alzheimer’s disease, by the additional collection of amyloid burden, measured by positron emission tomography (PET) imaging.
The current version of the raw AMYPAD PNHS dataset integrates information from 9 Parent Cohorts: ALFA+, AMYPAD DPMS, EMIF-AD (60++), EMIF-AD (90+), EPAD LCS, FACEHBI, FPACK, Microbiota, and UCL-2010-412. This dataset includes a total of 3266 participants. Of them, 1518 underwent a baseline amyloid PET that includes the visual read and the Centiloid quantification (1384 subjects), among other metrics. Moreover, 855 participants have (at least) one follow-up PET scan, 737 of them with Centiloid quantification. The participant’s clinical outcomes (e.g., cognition), disease (imaging) biomarkers, risk factors (e.g., genetics and environmental), and other relevant variables are included in the dataset.
Moreover, this version of the dataset includes the ‘raw’, ‘harmonized’, and ‘derived’ set of variables (further details can be found in the Data Access Request Procedure documents).
Data access
AMYPAD offers a way of accessing the data to academic researchers, institutions and companies from all over the world. This is shared through secure online Workspaces and you will need to make a formal request to access the imaging, clinical, and biomarker data for scientific research investigation and/or educational activities. The application can be performed via the FAIR Data Service of the Alzheimer’s Disease Data Initiative (https://fair.addi.ad-datainitiative.org/#/data/home).
You can find the data access request procedure for the AMYPAD PNHS here.
If you are requesting access to the AMYPAD PNHS, you should accept the responsible use of the data under the terms described here.
Requirements for publishing results
AMYPAD encourage the publication of any research arising from the AMYPAD PNHS. If results are published that were generated using the AMYPAD PNHS data, it is mandatory to acknowledge the AMYPAD Consortium and the grants that supported this IMI project. More details are provided in the document here, which outlines the policies for publication and the publication credits for those who use the AMYPAD PNHS data.
Acknowledgements and disclaimer
The AMYPAD project received funding from the Innovative Medicines Initiative 2 Joint undertaking under grant agreement No 115952. This Joint Undertaking received support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the views of the consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.